HER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030 Summary Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer constitutes approximately 20% of breast cancer cases and was historically associated with poor prognosis in the absence of effective treatments. The realization that introducing HER2-targeted therapies earlier into the disease management strategy could improve disease-free survival (DFS) has created a large market for HER2-directed therapies. Today, HER2+ breast cancer patients are living longer with their disease, thanks to established disease management strategies using regimens with Herceptin, Perjeta, and the antibody-drug conjuga......

Pompe Disease - Opportunity Assessment and Forecast to 2030 Summary Pompe Disease (PD), also known as glycogen storage disease II, is a recessive genetic metabolic disorder caused by a deficiency in the enzyme ?-glucosidase (GAA). GAA is normally responsible for hydrolyzing ?-1, 4 and ?-1, 6 linkages in various carbohydrates, including maltose, isomaltose, and glycogen. The absence or deficiency of GAA results in excessive storage of glycogen in cellular lysosomes. This inhibition can lead to cellular stress and injury. In PD, cardiac muscle tissue is severely affected alongside neurons in both the autonomic nervous system (ANS) and central nervous system (CNS). Scope - GlobalData's Pompe Disease - Opportunity Assessment and Forecast combines data from the Pharma Intelligence Center wi......

Postherpetic Neuralgia - Global Clinical Trials Review, H1, 2021 Summary GlobalData's clinical trial report, "Postherpetic Neuralgia - Global Clinical Trials Review, H1, 2021" provides an overview of Postherpetic Neuralgia Clinical trials scenario. This report provides top line data relating to the clinical trials on Postherpetic Neuralgia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma -......

Cytomegalovirus (HHV-5) Infections - Global Clinical Trials Review, H1, 2021 Summary GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections - Global Clinical Trials Review, H1, 2021" provides an overview of Cytomegalovirus (HHV-5) Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated us......

Fungal Infections - Global Clinical Trials Review, H1, 2021 Summary GlobalData's clinical trial report, "Fungal Infections - Global Clinical Trials Review, H1, 2021" provides an overview of Fungal Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Fungal Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials dat......